About Clairity
Clairity is a Boston-based medical technology company pioneering AI-powered breast cancer risk assessment through its flagship product, Clairity Breast (authorized under the name Allix5). Founded in 2020 by Dr. Connie Lehman, a Harvard Medical School professor and Yale-trained physician-scientist, the company has developed the first FDA-authorized, image-only AI platform that estimates a woman's five-year risk of developing breast cancer from a routine mammogram. The company's mission is to shift the standard of care for cancer from reactive diagnosis to proactive prevention. Clairity's technology unlocks new insights from radiological imaging data, accurately identifying individuals at highest risk of developing cancer regardless of race, ethnicity, or gender. The AI model was trained on millions of images and validated across more than 77,000 mammograms from five geographically distinct screening centers serving diverse patient populations. Clairity Breast complements existing clinical workflows and addresses widespread shortfalls in breast cancer risk assessment at scale. The platform enables clinicians to personalize care plans for each patient and evolve those plans over time, monitoring lifestyle choices, health changes, and family history. In February 2024, Beth Israel Deaconess Medical Center became the first medical center in the United States to offer this technology clinically. The company has raised $43 million in Series B funding and is backed by Santé Ventures and ACE Global Equity.
Mission & Story
Mission
Shift the standard of care for cancer from reactive diagnosis to proactive prevention.
Founding Story
Founded in 2020 by Dr. Connie Lehman, a Harvard Medical School professor and Yale-trained physician-scientist who has spent decades at the intersection of radiology and artificial intelligence. Dr. Lehman's career has focused on looking at mammograms differently and working on the early identification of cancer through computer aided diagnosis, deep learning, and predictive risk models.
Clinical Focus
Medical conditions and clinical areas addressed by Clairity.
Who It Serves
Milestones & Awards
Recent Milestones
First clinical patient received Clairity Breast score at Beth Israel Deaconess Medical Center in February 2024. Raised $43 million Series B financing. Incorporated into NCCN Guidelines for breast cancer screening with AI-based risk assessment beginning at age 35. Featured on NBC's TODAY Show. Dr. Connie Lehman named to TIME's 2026 TIME100 Health List and appointed CEO.
Awards & Recognition
Dr. Connie Lehman named to TIME's 2026 TIME100 Health List. First FDA-authorized image-only AI model for breast cancer risk prediction. Featured in NCCN Guidelines update.
Key Partnerships
Social & Media
Latest Updates
Changes in AI Mammogram Risk Scores Over Time Help Predict Future Breast Cancer
Dr. Connie Lehman on how Clairity predicts breast cancer
How Beth Israel is using AI to take screenings beyond the mammogram to assess breast cancer risk
Clairity Announces Update to NCCN Guidelines to Include AI Mammogram-Based Risk Tool to Identify Future Breast Cancer Risk in Women Missed by Traditional Methods
Meeting Patients Where They Are
Company Details
- Founded
- 2020
- Headquarters
- Boston, MA, USA
- Employees
- 1-10
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.